Nectar Lifesciences Limited (NECLIFE.NS)
- Previous Close
21.06 - Open
20.83 - Bid --
- Ask --
- Day's Range
20.02 - 21.00 - 52 Week Range
20.02 - 56.50 - Volume
512,768 - Avg. Volume
1,651,210 - Market Cap (intraday)
4.68B - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
27.80 - EPS (TTM)
0.75 - Earnings Date May 13, 2025 - May 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 21, 2020
- 1y Target Est
--
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company's active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
www.neclife.com1,686
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: NECLIFE.NS
View MorePerformance Overview: NECLIFE.NS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NECLIFE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NECLIFE.NS
View MoreValuation Measures
Market Cap
4.60B
Enterprise Value
10.63B
Trailing P/E
27.35
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.28
Price/Book (mrq)
0.43
Enterprise Value/Revenue
0.63
Enterprise Value/EBITDA
5.84
Financial Highlights
Profitability and Income Statement
Profit Margin
1.01%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
16.81B
Net Income Avi to Common (ttm)
170.01M
Diluted EPS (ttm)
0.75
Balance Sheet and Cash Flow
Total Cash (mrq)
187.35M
Total Debt/Equity (mrq)
58.37%
Levered Free Cash Flow (ttm)
--